# PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

> **NCT03809988** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 198 (actual)

## Conditions studied

- Breast Cancer
- Advanced Breast Cancer
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Endocrine therapy

## Key facts

- **NCT ID:** NCT03809988
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809988, "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03809988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*